Is SNDX a Buy or a Sell? The Bull and Bear Case (2026)

The most optimistic published target on SNDX is $57.00, +190.1% from the $19.65 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

The most pessimistic published target is $26.00, +32.3% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Syndax Pharmaceuticals is worth if the risks below bite instead of the drivers above.

Revuforj no longer has the menin inhibitor class to itself. Kura Oncology and Kyowa Kirin won FDA approval for ziftomenib (Komzifti) in November 2025 in relapsed or refractory NPM1-mutated AML, the same population Syndax entered three weeks earlier, and began selling on November 21, 2025. Komzifti is dosed once daily. Both labels carry boxed warnings, including differentiation syndrome and QTc prolongation, so the competition is likely to be fought on dosing convenience, payer access and combination data rather than on a clean safety separation. Kura's partner paid $330M upfront with up to $1.1B in milestones, which funds a serious commercial effort against a Syndax field force that is already carrying two products. The balance sheet is the second issue. Total stockholders' equity was $15.1M at June 30, 2026 against $688.6M of liabilities, and the accumulated deficit stands at $1.6B. The financing is unusual in shape: a $350M upfront from Royalty Pharma in November 2024 that sells 13.8% of US Niktimvo net sales with aggregate payments capped at $822.5M, accounted for as debt, plus $250M of 2.25% convertible senior notes due June 2031 issued in June 2026 at a conversion price near $24.76. Royalty interest expense alone was $12.1M in the second quarter and $24.0M for the half, and it grows as Niktimvo grows. If Niktimvo performs, Syndax pays back up to 2.35 times what it received. The converts add about 10.1M potential shares against 89.4M outstanding. Beyond that, revenue depends on two products in narrow later-line indications, both under UCB and AbbVie-related royalty obligations, with the frontline expansions still unproven. The first quarter of 2026 already showed how sensitive the line is to the January payer reset, falling to $64.9M from $68.7M in the fourth quarter of 2025 despite underlying demand growth.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding SNDX already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

11 analysts cover SNDX, with an average target of $37.55 (+91.1% against $19.65) and a split of 12 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the SNDX forecast and price target page.

• Revenue (TTM): ~$252.3M for the twelve months to June 30, 2026, against $172.4M in fiscal 2025 and $23.7M in fiscal 2024. The quarterly path was $68.7M in 4Q25, $64.9M in 1Q26 (a sequential dip driven by the January payer and gross-to-net reset, not by demand) and $72.8M in 2Q26, the last of which was up 92% year over year.
• Product mix (the line that misleads screeners): Of 2Q26's $72.8M, $54.7M was Revuforj net product revenue and $18.1M was collaboration revenue representing Syndax's 50% share of Niktimvo net commercial profit. Incyte separately reported $60.3M of Niktimvo net sales in the quarter. Combined branded sales of the two medicines were therefore ~$115.0M in 2Q26 and over $275M across full-year 2025 ($124.8M Revuforj plus $151.6M Niktimvo), well above the reported revenue line.
• Earnings and EPS: Net loss of $49.4M, or $0.55 per share, in 2Q26 versus $71.8M and $0.83 a year earlier; $92.0M and $1.04 per share for the first half of 2026 versus $156.7M and $1.82. Full-year 2025 net loss was $285.4M and 2024 was $318.8M. Operating loss narrowed to $40.0M in 2Q26 from $69.4M. There is no P/E, and there has never been an annual profit.
• Operating expenses and guidance: 2Q26 R&D was $68.0M (from $62.2M), SG&A $41.5M (from $43.8M) and cost of product sales $3.2M, for $112.8M of total opex. First-half opex was $211.8M against $210.9M a year earlier, so spend is roughly flat while revenue grew 138%. Guidance for full-year 2026 is approximately $400M of R&D plus SG&A excluding ~$50M of estimated non-cash stock compensation, down from $438.5M actual in 2025.
• Cash flow and balance sheet: Cash, cash equivalents and short and long-term investments of $575.1M at June 30, 2026, up from $394.1M at December 31, 2025 after the $250M convertible issue. Operating cash burn fell to $80.6M in the first half of 2026 from $183.0M a year earlier. Total assets $703.7M, total liabilities $688.6M (including a $344.0M royalty interest financing liability and a $244.1M convertible note liability) and stockholders' equity of just $15.1M. Accumulated deficit ~$1.6B.
• Market pricing: ~$19.65 a share in August 2026 for a market capitalisation of ~$1.75B, against a 52-week range of $12.99 to $25.59. Roughly 89.2M common shares outstanding (89.4M including pre-funded warrants), rising to ~116.3M fully diluted once options, RSUs and the 10.1M convertible conversion shares are counted. Those figures work out to ~6.9x trailing sales and roughly 7x EV/sales adjusting for cash and the two debt-like instruments. No dividend, no P/E, beta ~0.37.

Seven times sales is not a demanding multiple for a biotech growing revenue at triple digits, and the reason it is not higher is visible in the structure rather than the growth rate. Half the franchise arrives as a profit share, the Royalty Pharma instrument skims 13.8% of US Niktimvo sales before anything reaches Syndax, and both drugs are approved only in later-line settings where the patient pool is finite. Twelve covering analysts carried a mean target near $37.55 in August 2026, which is a frontline-expansion number rather than a run-rate one.

Rather than asking whether SNDX is a buy in the abstract, it tends to help to answer four questions:

• Thesis: do you believe the bull case above, and is it still true today?
• Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
• Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
• Overlap: check whether you already hold SNDX indirectly through an index or sector ETF before adding more.

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

• Bull case breaks if: Revuforj moving from KMT2A into the far larger NPM1 population stalls in the reported numbers rather than in the narrative around them.
• Bear case breaks if: revuforj no longer has the menin inhibitor class to itself fails to materialise over several reporting periods while the drivers keep compounding.
• Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the SNDX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about SNDX against your real portfolio and see your actual exposure before deciding.